missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. 18514261

Daxx Antibody (PCRP-DAXX-8B7), DyLight 594, Novus Biologicals™

Mouse Monoclonal Antibody

Brand:  Novus Biologicals NBP3-08740DL594

4768.00 SEK valid until 2025-03-28
Use promo code "25306" to get your promotional price.

Product Code. 18514261

  • 5960.00 SEK / 100µL

Please to purchase this item. Need a web account? Register with us today!

Explore more special offers
This item is not returnable. View return policy

Description

Description

Daxx Monoclonal antibody specifically detects Daxx in Human samples. It is validated for Flow Cytometry, Immunocytochemistry/ Immunofluorescence, Protein Array
TRUSTED_SUSTAINABILITY
Specifications

Specifications

Daxx
Monoclonal
DyLight 594
BING2, CENP-C binding protein, DAP6MGC126245, Daxx, death domain-associated protein 6, death-associated protein 6, death-domain associated protein, EAP1, ETS1-associated protein 1, Fas death domain-associated protein, Fas-binding protein, hDaxx, MGC126246
Recombinant full-length human Daxx protein (Uniprot: Q9UER7)
100 μg
Apoptosis, Cancer, Tumor Suppressors
1616
Store at 4°C in the dark.
IgG2b κ
Flow Cytometry, Immunofluorescence, Protein Array
PCRP-DAXX-8B7
50mM Sodium Borate
Mouse
Protein A or G purified
RUO
Primary
Human
Purified
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Certificates
Special Offers

Special Offers

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.